Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23366191 | 0.97 | MMP13 (0.39) | MMP13PTGER4MMEECE1GPR132 | |
| SCHEMBL23366235 | 0.97 | MMP13 (0.39) | MMP13PTGER4MMEECE1GPR132 | |
| SCHEMBL23366190 | 0.97 | MMP13 (0.39) | MMP13PTGER4MMEECE1GPR132 | |
| SCHEMBL24180296 | 0.95 | MME (0.35) | MMP13PTGER4MMEECE1GPR132 | |
| SCHEMBL24180300 | 0.92 | MME (0.37) | MMP13PTGER4MMEECE1GPR132 | |
| SCHEMBL24180289 | 0.91 | PSMB1 (0.34) | MMP13PTGER4MMEECE1CAPN1 | |
| SCHEMBL24180303 | 0.88 | CTSK (0.39) | MMEECE1CAPN1CASP3CTSK | |
| SCHEMBL23366164 | 0.81 | MME (0.49) | MMEECE1CASP3 | |
| SCHEMBL23366222 | 0.81 | MME (0.49) | MMEECE1CASP3 | |
| SCHEMBL23366211 | 0.81 | MME (0.49) | MMEECE1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007274-B2 | Compounds for medicinal applications | AusVir Therapeutics Pty Ltd (AU) | 2021-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007274-B2 | Compounds for medicinal applications | HAVCR2, ENGASE, DNPEP | MMP13 961/4885PTGER4 2023/4885MME 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.